ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis

ClinicalTrials.gov ID: NCT04486716

Public ClinicalTrials.gov record NCT04486716. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Single-arm, Prospective, Multi-center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Relapsing Multiple Sclerosis Who Discontinue Intravenously Delivered Anti-CD20 Monoclonal Antibody (aCD20 mAb) Therapy (OLIKOS)

Study identification

NCT ID
NCT04486716
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
111 participants

Conditions and interventions

Interventions

  • Ofatumumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 60 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 18, 2020
Primary completion
Nov 19, 2023
Completion
Oct 20, 2024
Last update posted
Jan 12, 2026

2020 – 2024

United States locations

U.S. sites
19
U.S. states
13
U.S. cities
18
Facility City State ZIP Site status
Alabama Neurology Associates PC Birmingham Alabama 35209
Ctr for Neurology and Spine Phoenix Arizona 85018
Neuro Center Pomona California 91767
UC Health Neuroscience Ctr Aurora Colorado 80045
Infinity Clinical Research LLC Hollywood Florida 33024
AMO Corporation Tallahassee Florida 32312
University Of South Florida Tampa Florida 33612
International Neurorehab Institute Lutherville Maryland 21093
Dana Farber Cancer Institute Boston Massachusetts 02115
Beth Israel Deaconess Medical Cente Boston Massachusetts 02215
Neurology Center of New England PC Foxborough Massachusetts 02035
Dragonfly Research LLC Wellesley Massachusetts 02481
Cleveland Clinic Foundation Las Vegas Nevada 89106
Ms Ctr Of Northeastern Ny Latham New York 12110
Columbus Neuroscience Westerville Ohio 43082
Sibyl Wray MD Neurology PC Knoxville Tennessee 37922
Parkland Health and Hospital Systems Dallas Texas 75325
Central TX Neuro Consultants P A Round Rock Texas 78681
Swedish Neuroscience Institute Seattle Washington 98122

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04486716, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 12, 2026 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04486716 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →